Table 6.
New agents for Hodgkin lymphoma currently under clinical development
| Target | Agent | Phase | Response (PR+CR) (%) | Reference(s) |
|---|---|---|---|---|
| CD30 | Brentuximab, Vedotin | I | 50 | [94] |
| CD20 | Rituximab | II | 22 | [95] |
| mTOR | Everolimus | II | 47 | [96] |
| JAK2 | SB1518 | I | - | [97] |
| HDACs | LBH 589 | II | 26 | [98] |
| SAHA | II | 4 | [99] | |
| MGCD0103 | II | 30 | [100] | |
| AKT | MK2206 | I | - | - |
| NF-kB | Bortezomib | II | 7 | [101] |
| Target unknown | Lenalidomide | II | 13 to 17 | [102,103] |
CR, complete response; HDACs, histone deacetylases; JAK2, Janus kinase 2; mTOR, mammalian target of rapamycin; NF, nuclear factor; PR, partial response.